Loading
XT
XORTX Therapeutics Inc. Stock: price and insider trades · Canada
XORTX Therapeutics Inc.: what insiders have been doing
This page follows insider dealings at XORTX Therapeutics Inc. as filed with SEDI. Nothing new has been filed by managers of XORTX Therapeutics Inc. in twelve months, the latest record being from 30 July 2025.
The full history, which starts in 2021, counts 47 purchases against no sales.
These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.
Insider Decl.
59
Thresholds
n/a
Buy Volume
€85,360
47 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleAllen Warren Davidoff18 buys
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 30 July 2025
Declarations59 total
8,191 shares@ CA$1.0015.1% of flowCommon SharesTSXSEDI:4552404
Canonical exit: 20 Oct 2025 (T+90)
500 shares@ CA$1.181.1% of flowCommon SharesTSXSEDI:4536745
Canonical exit: 21 Sept 2025 (T+90)
300 shares@ CA$1.200.7% of flowCommon SharesTSXSEDI:4536744
Canonical exit: 21 Sept 2025 (T+90)
1,000 shares@ CA$1.02381.9% of flowCommon SharesTSXSEDI:4514472
Canonical exit: 10 Aug 2025 (T+90)
2,000 shares@ CA$1.42955.4% of flowCommon SharesTSXSEDI:4514475
Canonical exit: 12 Aug 2025 (T+90)
2,000 shares@ CA$1.42655.4% of flowCommon SharesTSXSEDI:4514474
Canonical exit: 12 Aug 2025 (T+90)
300 shares@ CA$1.460.8% of flowCommon SharesTSXSEDI:4514473
Canonical exit: 10 Aug 2025 (T+90)
1,000 shares@ CA$1.283.4% of flowCommon SharesTSXSEDI:4499334
Canonical exit: 14 Jul 2025 (T+90)
3,000 shares@ CA$1.2710.2% of flowCommon SharesTSXSEDI:4499331
Canonical exit: 14 Jul 2025 (T+90)
2,000 shares@ CA$1.296.9% of flowCommon SharesTSXSEDI:4499332
Canonical exit: 14 Jul 2025 (T+90)
600 shares@ CA$1.521.8% of flowCommon SharesTSXSEDI:4463642
Canonical exit: 29 May 2025 (T+90)
2,500 shares@ CA$1.527.4% of flowCommon SharesTSXSEDI:4463639
Canonical exit: 29 May 2025 (T+90)
3,000 shares@ CA$1.366.0% of flowCommon SharesTSXSEDI:4454900
Canonical exit: 15 May 2025 (T+90)
2,500 shares@ CA$1.294.8% of flowCommon SharesTSXSEDI:4454901
Canonical exit: 15 May 2025 (T+90)
3,000 shares@ CA$1.315.8% of flowCommon SharesTSXSEDI:4454896
Canonical exit: 15 May 2025 (T+90)
2,000 shares@ CA$1.343.9% of flowCommon SharesTSXSEDI:4452352
Canonical exit: 8 May 2025 (T+90)
2,500 shares@ CA$1.365.0% of flowCommon SharesTSXSEDI:4452354
Canonical exit: 8 May 2025 (T+90)
10,000 shares@ CA$1.4918.1% of flowCommon SharesTSXSEDI:4438231
Canonical exit: 16 Apr 2025 (T+90)
10,000 shares@ CA$3.0023.0% of flowCommon SharesTSXSEDI:4261282
600 shares@ CA$2.895100.0% of flowCommon SharesTSXSEDI:4232098
Canonical exit: 26 Mar 2024 (T+90)
13,408 sharesCommon SharesTSXSEDI:4225411
415,660 sharesCommon SharesTSXSEDI:4225073
Common SharesTSXSEDI:4225406
Common SharesTSXSEDI:4225407
42,160 sharesCommon SharesTSXSEDI:4225412
25 of 59 declarations
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for kidney diseases. It is listed on the Toronto Stock Exchange under the symbol XTSE.
